Frank, age 58, professor, is a symptomatic patient with moderate COPD not yet on maintenance therapy and has had no exacerbations in the last 12 months.
Shortness of breath
Regular rescue medication use
Pulling away from normal activities
According to GOLD 2020, relieving and reducing impact of symptoms are key management goals for patients with COPD
For the last 4 years, the GOLD report has supported starting symptomatic patients on a LAMA/LABA
States that treatable traits, such as symptoms, should guide management of COPD
Does not include ICS/LABA as initial treatment in many patients
ANORO was studied in patients with moderate or worse COPD.
*Defined as statistically significant improvements in lung function relative to its individual components and placebo in a 24-week, randomized, double-blind study in patients with COPD (N=1532).